Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2008-1-31
pubmed:abstractText
Extracellular matrix degradation and increased proteolytic enzyme (matrix metalloproteinase (MMP)) activity characterise abdominal aortic aneurysm formation. Post-stenotic dilatation of ascending aorta is associated with aortic stenosis and regurgitation, haemodynamically normal bicuspid aortic valve (BAV) and following AV replacement. We aimed to determine an association between ascending aortic pathology and abnormal AV, with particular reference to MMPs, and ascertain differences between BAV and tricuspid (TAV) AV. Subset of the study population (n=19) with a preoperative ascending aorta of >4 cm was analysed. Samples of ascending aorta and AV were obtained from 82 patients (TAV, n=54, BAV, n=28) undergoing surgery. Gene expression of MMP-1, -2, -9 and tissue inhibitor of metalloproteinase (TIMP)-1 and -2 was quantified by real-time RT-PCR. No significant difference was seen in gene expression level of MMPs, TIMPs and ratio of MMPs/TIMPs in ascending aorta and AV between patients with BAV and TAV. MMP-2/TIMP-1 in ascending aorta was greater in BAV, in the subset of patients with preoperative aortic dilatation (P<0.05). No difference exists in gene expression of MMPs in ascending aorta and AV between patients with BAV and TAV. However, patients with larger aortic diameters have increased MMP-2/TIMP-1. Modifying MMP expression may have a role in development of aneurysms.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1569-9285
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
37-40
pubmed:dateRevised
2008-2-27
pubmed:meshHeading
pubmed-meshheading:18025061-Aged, pubmed-meshheading:18025061-Aorta, Thoracic, pubmed-meshheading:18025061-Aortic Aneurysm, Thoracic, pubmed-meshheading:18025061-Blood Vessel Prosthesis Implantation, pubmed-meshheading:18025061-Disease Progression, pubmed-meshheading:18025061-Echocardiography, pubmed-meshheading:18025061-Female, pubmed-meshheading:18025061-Follow-Up Studies, pubmed-meshheading:18025061-Gene Expression, pubmed-meshheading:18025061-Heart Valve Diseases, pubmed-meshheading:18025061-Heart Valve Prosthesis Implantation, pubmed-meshheading:18025061-Humans, pubmed-meshheading:18025061-Male, pubmed-meshheading:18025061-Matrix Metalloproteinase 1, pubmed-meshheading:18025061-Matrix Metalloproteinase 2, pubmed-meshheading:18025061-Matrix Metalloproteinase 9, pubmed-meshheading:18025061-Matrix Metalloproteinases, pubmed-meshheading:18025061-Middle Aged, pubmed-meshheading:18025061-Mitral Valve, pubmed-meshheading:18025061-Prognosis, pubmed-meshheading:18025061-Prospective Studies, pubmed-meshheading:18025061-RNA, pubmed-meshheading:18025061-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:18025061-Tissue Inhibitor of Metalloproteinase-1, pubmed-meshheading:18025061-Tissue Inhibitor of Metalloproteinase-2
pubmed:year
2008
pubmed:articleTitle
Matrix metalloproteinase expression in the ascending aorta and aortic valve.
pubmed:affiliation
Department of Cardiac Surgery and Cardiac and Vascular Sciences, St. George's Hospital, University of London, London, UK.
pubmed:publicationType
Journal Article, Comparative Study